Advanced Search

RHCT-138 (ATCC® CRL-2563™)

Organism: Oryctolagus cuniculus, rabbit  /  Cell Type: infected with HTLV-I  /  Disease: cutaneous T cell lymphoma

Permits and Restrictions

View Permits View Restrictions
Organism Oryctolagus cuniculus, rabbit
Cell Type infected with HTLV-I
Product Format frozen
Morphology lymphoblast
Culture Properties suspension, multicell aggregates
Biosafety Level 2 Cells infected with HTLV-I virus

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease cutaneous T cell lymphoma
Age 4.5 years
Gender male
Applications
The RHCT-138 cell line was derived from a skin biopsy taken from an HTLV-1 infected rabbit (X138) with cutaneous T cell lymphoma (CTCL).
Storage Conditions liquid nitrogen vapor phase
Derivation
The RHCT-138 cell line was derived from a skin biopsy taken from an HTLV-1 infected rabbit (X138) with cutaneous T cell lymphoma (CTCL).
The rabbit developed chronic HTLV-1 infection after inoculation with the infected rabbit T cell line RH/K34 (see ATCC CRL-2560).
Approximately 20 months after inoculation, the rabbit developed a generalized exfoliative papillated dermatopathy. Cutaneous lesions were biopsied.
Clinical Data
male
Genes Expressed
HTLV-I (human T cell leukemia virus)
Cellular Products
HTLV-I (human T cell leukemia virus)
Comments
The RHCT-138 cell line was derived from a skin biopsy taken from an HTLV-1 infected rabbit (X138) with cutaneous T cell lymphoma (CTCL).
The rabbit developed chronic HTLV-1 infection after inoculation with the infected rabbit T cell line RH/K34 (see ATCC CRL-2560).
Approximately 20 months after inoculation, the rabbit developed a generalized exfoliative papillated dermatopathy. Cutaneous lesions were biopsied.
The cell line harbors productively infected, monoclonally integrated, full length HTLV-1.
The HTLV-1 sequences in the skin likely represent the presence of infected T cells in epidermotropic lymphoid infiltrates.
Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate supplemented with an additional 2 mM L-glutamine, 80%; fetal bovine serum, 20%
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 X 10(5) viable cells/ml.
Interval: Maintain cultures at cell concentrations between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Name of Depositor RM Simpson
Year of Origin February, 1997
References

Simpson RM, et al. Cutaneous manifestations of human T cell leukemia virus type I infection in an experimental model. J. Infect. Dis. 173: 722-726, 1996. PubMed: 8627039

Kindt TJ, et al. Passage of human T-cell leukemia virus type-1 during progression to cutaneous T-cell lymphoma results in myelopathic disease in an HTLV-1 infection model. Microbes Infect. 2: 1139-1146, 2000. PubMed: 11008104

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Restrictions

1. This cell line was deposited at the ATCC by Dr. R. Mark Simpson and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of these cells, or their products must first be negotiated with the National Institute of Allergy and Infectious Diseases (NIAID) Office of Technology Development (OTD), Building 31, Room 3B-62 31 Center Drive, MSC 2137 Bethesda, MD 20892-2137 TEL: 301-496-2644 FAX: 301-402-7123
References

Simpson RM, et al. Cutaneous manifestations of human T cell leukemia virus type I infection in an experimental model. J. Infect. Dis. 173: 722-726, 1996. PubMed: 8627039

Kindt TJ, et al. Passage of human T-cell leukemia virus type-1 during progression to cutaneous T-cell lymphoma results in myelopathic disease in an HTLV-1 infection model. Microbes Infect. 2: 1139-1146, 2000. PubMed: 11008104